LAT1 and the development of anabolic resistance
LAT1 and the development of anabolic resistance
批准号:
9122262
负责人:
Keith Baar
金额:
$8.15万
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-07-01 至 2017-04-30
关键词:
AddressAgeAgingAmericanAmericasAnimalsAreaBiogenesisBiologyClinicalCoronary ArteriosclerosisDataDevelopmentDirect CostsDiseaseDrug DesignElderlyEventExerciseFatigueGoalsGrowthHealthInterventionKnockout MiceLaboratoriesLeadLeucineLongevityMaintenanceMeasuresMetabolismModerate ExerciseMolecularMuscleMuscle ProteinsNon-Insulin-Dependent Diabetes MellitusObesityOne-Step dentin bonding systemPharmaceutical PreparationsPopulationProcessProtein BiosynthesisProtein KinaseProteinsPublic HealthPublishingQuality of lifeRennieResearchResistanceResistance developmentRibosomesRoleSkeletal MuscleTechniquesTestingTimeWorkageddrug developmenteconomic costeffective therapyfeedingfightingfrailtyhuman FRAP1 proteinimprovedinnovationmenmortalitymuscle formmuscle hypertrophymuscle strengthnovelnutritionoverexpressionpreventresearch studyresponsesarcopeniatreatment strategyuptakeyoung adult
中文摘要
描述(由申请人提供):肌肉减少症,由于衰老导致的肌肉质量损失,导致或加重一系列衰弱性疾病,包括冠状动脉疾病、肥胖症、2型糖尿病和虚弱。尽管肌肉质量对健康和生活质量至关重要,但从营养和活动到肌肉蛋白质合成,质量和力量变化的分子链事件仍然知之甚少。这项研究旨在研究有助于肌肉力量的关键因素,最终目标是提高数百万美国人的寿命和生活质量。具体来说,我们将研究肌肉中的主要亮氨酸转运蛋白LAT 1在肌肉减少症的发展中所起的作用。由于亮氨酸的摄取是合成代谢对抗阻运动和蛋白质喂养的反应所必需的,因此这项工作的目的是确定LAT 1在合成代谢抵抗中的作用,并开发一种维持肌肉质量和力量的药理学策略。基于我们先前在这一领域发表的研究和强有力的初步数据,我们提出了一个工作假设,即肌肉中mTOR激活和核糖体生物合成减少会导致合成代谢抵抗。我们将通过检查这三个具体目标来检验这一假设:1)确定LAT 1的老化或丢失是否赋予对负荷的合成代谢抗性; 2)确定LAT 1的丢失是否赋予对蛋白质喂养的合成代谢抗性;以及3)确定增加核糖体质量是否逆转合成代谢抗性。这项极具创新性的提案首次使用新技术在多个水平上测量核糖体生物合成,探索了肌肉生物学中的这一基本问题。这项研究的意义是双重的:1)它将有助于对导致肌肉减少症的分子事件的基本理解,2)它将验证一种简单的药物治疗策略,可以增加肌肉质量,从而提高生活质量并降低人群的死亡率。成功完成这一应用程序是朝着我们实验室的长期目标迈出的一步:在不需要运动的情况下创造更大,更强,更耐疲劳的肌肉。
英文摘要
DESCRIPTION (provided by applicant): Sarcopenia, the loss of muscle mass due to aging, causes or aggravates a range of debilitating conditions including coronary artery disease, obesity, type 2 diabetes, and frailty. Even though muscle mass is essential for health and quality of life, the molecular chain of events that lead from nutrition and activity to a change in muscle protein synthesis, mass and strength remains poorly understood. This study aims to examine critical factors that contribute to muscle strength, with the ultimate goal of improving the longevity and quality of life in millions of Americans. Specifically, we will look at the role playd by the primary leucine transporter in muscle, LAT1, in the development of sarcopenia. Since leucine uptake is required for the anabolic response to both resistance exercise and protein feeding, the objective of this work is to determine the role of LAT1 in anabolic resistance and develop a pharmacological strategy to maintain muscle mass and strength. Building on our previously published research in this area, and strong preliminary data, we have developed the working hypothesis that decreased mTOR activation and ribosome biogenesis in muscle results in anabolic resistance. We will test this hypothesis by examining these three specific aims: 1) Determine whether aging or loss of LAT1 imparts anabolic resistance to loading; 2) Determine whether loss of LAT1 imparts anabolic resistance to protein feeding; and 3) Determine whether increasing ribosome mass reverses anabolic resistance. This highly innovative proposal explores this essential question in muscle biology using novel techniques to measure ribosome biogenesis at multiple levels for the first time. The significance of this research is two-fold: 1)It will contribute to a basic understanding of the molecular events leading to sarcopenia, and 2) It will validate a simple drug treatment strategy that can increase muscle mass and thus improve quality of life and reduce mortality in the population. Successful completion of this application i one step towards the long-term objective of our laboratory: to create bigger, stronger, and more fatigue resistant muscles without the need for exercise.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
University of California Davis Advancing Diversity in Aging Research Scholars Program
-
批准号:10238776
-
项目类别:
-
资助金额:$35.13万
-
财政年份:2020
-
负责人:Keith Baar
-
依托单位:
University of California Davis Advancing Diversity in Aging Research Scholars Program
-
批准号:10435495
-
项目类别:
-
资助金额:$35.13万
-
财政年份:2020
-
负责人:Keith Baar
-
依托单位:
University of California Davis Advancing Diversity in Aging Research Scholars Program
-
批准号:10684027
-
项目类别:
-
资助金额:$35.13万
-
财政年份:2020
-
负责人:Keith Baar
-
依托单位:
Mechanisms Underlying Improved Health Span on a Short-Term Ketogenic Diet
-
批准号:10398864
-
项目类别:
-
资助金额:$35.82万
-
财政年份:2019
-
负责人:Keith Baar
-
依托单位:
Mechanisms Underlying Improved Health Span on a Short-Term Ketogenic Diet
-
批准号:10153626
-
项目类别:
-
资助金额:$36.45万
-
财政年份:2019
-
负责人:Keith Baar
-
依托单位:
Mechanisms Underlying Improved Health Span on a Short-Term Ketogenic Diet
-
批准号:10685461
-
项目类别:
-
资助金额:$36.5万
-
财政年份:2019
-
负责人:Keith Baar
-
依托单位:
MoTrPAC: UC Preclinical Animal Study Site
-
批准号:9517521
-
项目类别:
-
资助金额:$4.37万
-
财政年份:2016
-
负责人:Keith Baar
-
依托单位:
MoTrPAC: UC Preclinical Animal Study Site
-
批准号:9246756
-
项目类别:
-
资助金额:$2.36万
-
财政年份:2016
-
负责人:Keith Baar
-
依托单位:
LAT1 and the development of anabolic resistance
-
批准号:9295905
-
项目类别:
-
资助金额:$31.12万
-
财政年份:2014
-
负责人:Keith Baar
-
依托单位:
LAT1 and the development of anabolic resistance
-
批准号:9052680
-
项目类别:
-
资助金额:$39.37万
-
财政年份:2014
-
负责人:Keith Baar
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: